Call for Abstract
International Conference on Frontiers in Lung Cancer , will be organized around the theme “Prodigious Discoveries in Lung Cancer”
Lung Cancer 2019 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Lung Cancer 2019
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Bronchial adenoma is a rare type of cancer that starts in the mucous glands and ducts of the lung airways or trachea, and in the salivary glands. Though "Adenoma" means a noncancerous tumor, most bronchial adenomas are cancer and can spread to other parts of the body. Yet they often grow slowly and are treatable.
- Track 1-1Carcinoid tumors
- Track 1-2Adenoid cystic carcinoma
- Track 1-3Mucoepidermoid carcinoma
Only a fraction of cigarette smokers develops lung cancer, suggesting that people differ in their susceptibility to this disease. We investigated whether differences in DNA Repair Capacity (DRC) for repairing tobacco carcinogen-induced DNA damage are associated with differential susceptibility to lung cancer.
- Track 2-1Cell Lung Cancer Adhesion Molecules
- Track 2-2Genetic Mutations
- Track 2-3Gene Silencing
- Track 2-4Chromosomal Changes
- Track 2-5Genomic Instability
Small cell lung cancer (SCLC) makes up less than 20% of lung cancers and is typically caused by tobacco smoking. It often starts in the bronchi, then quickly grows and spreads to other parts of the body, including the lymph nodes.
Non-small cell lung cancer (NSCLC) makes up about 85% of diagnosed lung cancers. These includes all kinds of epithelial lung cancer excluding the small cell lung carcinoma types and are generally more insensitive to chemotherapy.
- Track 3-1Adenocarcinoma
- Track 3-2Squamous Cell Carcinoma
- Track 3-3Large Cell Carcinoma
- Track 3-4Adenosquamous Carcinoma
- Track 3-5Carcomatoid Carcinoma
- Track 3-6Lung Carcinoid Tumors
- Track 3-7Adenoid Cystic Carcinoma
- Track 3-8Small Cell Lung Cancer Staging
- Track 3-9Non-Small Cell Lung Cancer Staging
Risk factors increase an individual’s chance of developing cancer. Risk factors for lung cancer includ
- Tobacco smoking
- Contact with radon, asbestos or other cancer-causing agents
- Personal history of smoking related cancer
- Family history of lung cancer
Lung cancer symptoms may include chronic cough, breathing changes, chest ache, wheezing, hoarse voice, tiredness, weight loss, headache and even bone pain. In certain chronic lung diseases, people with lung cancer don't have symptoms until the cancer is advanced.
- Track 4-1Smoking of Tobacco
- Track 4-2Family History of Lung Cancer
- Track 4-3Occupational Hazards
- Track 4-4Bronchorrhea
- Track 4-5Coughing up Blood
- Track 4-6Weight Loss with Unknown Cause
Lung disease ranges from bronchitis and pneumonia to pulmonary hypertension. Lung function tests and X-rays are used to diagnosis the problem. Many symptoms can be eased with proper treatment. If not treated they may directly or indirectly lead to lung cancer.
- Track 5-1Tuberculosis
- Track 5-2COPD
- Track 5-3Asthma
- Track 5-4Bronchitis
- Track 5-5Pneumonia
- Track 5-6Cystic Fibrosis
- Track 5-7Pulmonary Hypertension
- Track 5-8Tuberous Sclerosis Complex (TSC)
- Track 5-9Reactive Airway Disease
- Track 5-10Allergies
Alpha-1 antitrypsin lack (Alpha1-antitrypsin insufficiency, A1AD, or AATD) is a hereditary issue that causes faulty creation of alpha-1 antitrypsin (A1AT), prompting diminished A1AT movement in the blood and lungs, and affidavit of intemperate irregular A1AT protein in liver cells leading to lung illness and liver infection. Influenced people frequently develop emphysema, which is a lung infection caused by damage to alveoli. Alpha-1 antitrypsin deficiency (A1AD or AATD) is a genetic disorder that may result in lung disease or liver disease. Onset of lung problems is typically between 20 and 50 years old. This may result in shortness of breath, wheezing, or an increased risk of lung infections.
- Track 6-1Pneumothorax
- Track 6-2Bronchiectasis
- Track 6-3Emphysema
- Track 6-4Granulomatosis with polyangiitis
Genetic mutations that are known to play critical roles in the development and progression of NSCLC include:
- Epidermal growth factor receptor (EGFR) – the EGFR gene is responsible for a protein that helps a cell respond to its environment and can trigger cell growth, division, and survival.
- KRAS – the KRAS gene is involved in regulating cell division.
- Anaplastic lymphoma kinase (ALK) – the ALK gene provides instructions for a protein that plays an important role in cell growth, division, and maturation.
- Track 7-1Epidermal Growth Factor Receptor (EGFR)
- Track 7-2Kirsten RAS (KRAS)
- Track 7-3Anaplastic Lymphoma Kinase (ALK)
- Track 7-4Other Genetic Abnormalities in NSCLC
ARDS, or acute respiratory distress syndrome, is a lung condition that leads to low oxygen levels in the blood. ARDS can be life threatening because organs, such as the kidneys and brain, need oxygen-rich blood to work properly. Most people who develop ARDS are in the hospital for other serious health problems. Rarely, people who aren't hospitalized have health problems that lead to ARDS, such as severe pneumonia. Causes of ARDS includes infections, injuries, or other conditions that cause the lung's tiny blood vessels to leak more fluid than normal into the lungs' air sacs. This prevents the lungs from filling with air and moving enough oxygen into the bloodstream.
- Track 8-1What is ARDS
- Track 8-2Symptoms and Signs of ARDS
- Track 8-3Causes of ARDS
- Track 8-4Treatment of ARDS
Although primary lung tumor is rare in the pediatric population, a wide range of histopathological tumor types occur comprising mainly of broad spectrum of lesions. The most common type of primary lung tumor in children includes carcinoid tumor and pleuropulmonary blastoma. The latter is a rare lung cancer affecting primarily children and adolescents.
- Track 9-1Pleuropulmonary Blastoma (PPB)
- Track 9-2Types of PPB
- Track 9-3Diagnosis of PPB
- Track 9-4Treatment of PPB
The implementation of molecular biomarkers in routine practice continues to be challenging. First, physicians must know which biomarkers should be analyzed in routine practice and be aware that additional markers may soon become standard. In this context, regularly updated guidelines can support physicians in their decisions. Nevertheless, clinical implementation of molecular biomarkers may differ among regions based on prevalence of the biomarker, availability of test methods, and access to corresponding treatments.
- Track 10-1Aptahistochemistry for Identification of Lung Cancer Biomarkers
- Track 10-2Biomarkers of Different Histological Lung Cancer Types
- Track 10-3Biomarkers of Lung Cancer
- Track 10-4Conventional Protein Biomarkers of Lung Cancer
Lung cancer screening tests include chest X-rays, CT scans, and sputum cytology. Research is still being done into the effectiveness of screening since there are several types of lung cancer, some of which are hard to detect. Screening may not reduce mortality in lung cancer patients. One downside to testing is that false positives can result in unnecessary further tests that may have adverse effects.
- Track 11-1Low Dose Computer Tomography (LDCT)
- Track 11-2Screening Profile
- Track 11-3 Lactic Acid Dehydrogenase (LDH) Test
- Track 11-4Lung Cancer Diagnosis Using Aptamers
The detection and diagnosis of lung cancer and COPD can be evaluated by performing the following tests: spirometry, chest radiography, chemotherapy, immunotherapy, CT scan, arterial blood gas analysis, complete blood count, transthoracic ultrasonography and lung function tests. Spirometry measures the amount of airflow obstruction present and is generally done after the use of a bronchodilator. An arterial blood gas test measures the oxygen level in blood and the result can show how severe COPD is and whether patient need oxygen therapy. The differential diagnosis is also performed for testing the asthma, congestive heart failure and pulmonary embolism.
- Track 12-1 X-ray of Chest
- Track 12-2CT Scan of Chest and Upper Abdomen
- Track 12-3Bronchoscopy
- Track 12-4Thoracoscopy
- Track 12-5Mediastinoscopy
- Track 12-6FNA for Peripheral Tumors
- Track 12-7Bone scan and Cranial CT Scan
Lung cancer can rarely be detected in its earliest stages, when treatment is more likely to result in a cure. By the time symptoms appear, it’s often too late for curative surgery, leaving only treatments that aim to improve quality of life. Although researchers have made remarkable progress in chemotherapy for all stages of disease, most people diagnosed with symptomatic lung cancer do not survive. Over the past 50 years, the U.S. has seen an encouraging decline in the prevalence of smoking, through aggressive anti-tobacco campaigns and policies. However, this decline now appears to be slowing, while an unacceptably large population is at risk from lung cancer. Lung cancer is responsible for nearly 30 percent of all cancer deaths each year —more than that of breast cancer, prostate cancer and colon cancer combined. As the prime cause of cancer-related deaths in the nation, lung cancer receives far too little attention.
- Track 13-1Smoking Cessation
- Track 13-2Avoiding Secondhand Smoke
- Track 13-3Protection of Lungs at Work and Outdoors
- Track 13-4Testing Home for Radon
- Track 13-5Early Detection through Regular Screening
Even after careful selection, considering the stage, location and cell type of the cancer, the operative death rate of lung cancer surgery is about 4.4%. Hence surgery is only suitable for NSCLC stages 1A, 1B, 2A and 2B. In thoracotomy, the surgeon generally opens up the chest cavity by making an incision in the side of the chest and by spreading apart the ribs to gain access to the cancerous tissues.
- Track 14-1Video-assisted thoracic surgery (VATS)
- Track 14-2Robotic-assisted thoracic surgery
- Track 14-3Lobectomy
- Track 14-4Sublobar Resection
- Track 14-5Segmentectomy
- Track 14-6Pneumonectomy
- Track 14-7 Wedge resection
- Track 14-8Bronchoplastic Resection
Radiotherapy is often accompanied with chemotherapy to people with NSCLC who are ineligible for surgery. Continuous high fractionated accelerated radiotherapy (CHART) is recommended for people with NSCLC while chest radiotherapy is recommended for people with curable SCLC in addition to chemotherapy. Palliative radiotherapy to the chest is applied to both patients of NSCLC and SCLC to control the symptoms. With the help of targeting and imaging technologies, stereotactic radiation is used to treat early stage lung cancer.
- Track 15-1Radical Radiotherapy
- Track 15-2 Continuous High Fractionated Accelerated Radiotherapy (CHART)
- Track 15-3Brachytherapy
- Track 15-4Prophylactic Cranial Irradiation (PCI)
- Track 15-5Palliative Radiotherapy
Depending on the type of tumor, chemotherapy is used as the first-line treatment in both SCLC and NSCLC. Cisplatin and etopside are used along with radiation to treat early stage small cell lung carcinoma. They are also used in combination of carboplatin, gemcitabine, paclitaxel, vinorelbine, topotecan, and irinotecan. While in advanced non-small cell lung carcinoma, cisplatin and carboplatin are used to improve survival rates along with gemcitabine, paclitaxel, docetaxel, pemetrexed, etoposide and vinorelbine.
- Track 16-1Adjuvant Chemotherapy
- Track 16-2Pre-surgery Chemotherapy
- Track 16-3Adverse Drug Reaction
- Track 16-4Palliative care in Chemotherapy
Targeted therapy hinders the growth and spread of cancer cells by targeting specific genes or proteins of cancerous cells. The research to improve outcomes for patients with NSCLC has only just begun by developing treatments to target additional pathways. Since all tumors don’t have the same target, a lot of tests have to be conducted to identify the genes, proteins and other factors in the tumor to deliver the most effective treatment. Bevacizumab, Ramucirumab, Necitumumab, Afatinib, Erlotinib, Alectinib, Ceritinib, Crizotinib and Brigatinib are some of the drugs used in clinical trials for targeted therapy for lung cancer.
- Track 17-1Anti-angiogenesis therapy
- Track 17-2 Epidermal growth factor receptor (EGFR) inhibitors
- Track 17-3Drugs targeting ALK gene mutations
- Track 17-4 Drugs targeting other genetic changes
When other therapies are ineffective, immunotherapy may offer significant benefit to lung cancer patients. Immunotherapy uses materials made inside body or in a laboratory to boost the body’s natural defense system against tumor cells. The immunotherapy drugs, nivolumab (Opdivo) and pembrolizumab (Keytruda) are checkpoint inhibitors that target the PD-1 protein, which strengthens the immune response against the cancers. Atezolizumab (Tecentriq) is a drug that targets PD-L1, a protein related to PD-1 that is found on some tumor cells and immune cells. A better understanding of the role of immune checkpoints in the cancer immunity cycle and advancements in computational and bioinformatics platforms enabled the development of cancer neoantigen vaccination strategies.
- Track 18-1 Advances in Molecular Therapy
- Track 18-2Immune Checkpoint Inhibition in Lung Cancer
- Track 18-3 CIMA vax